Montreal, March 20, 2017– Colorectal cancer is the third-most common form of cancer in Canada, second only to breast cancer in women and prostate cancer in men. Early screening is essential to improving the chances of a cure.
"With targeted radiation therapy, we are now able to offer efficient treatment to our patients," says Dr. Té Vuong, Jewish General Hospital Chief of Radiation Oncology. “After chemotherapy, 10% to 15% of patients of patients no longer have a cancerous mass when we operate on them."
"In taking full advantage of the latest scientific developments, our healthcare network is proud to provide colorectal cancer patients with therapies that are increasingly effective and that, in some cases, have even made surgery unnecessary," says Dr. Lawrence Rosenberg, President and CEO of CIUSSS West-Central Montreal. "However, our most pressing objective is to encourage members of the public to take preventive measures, such as having a colonoscopy on a regular basis, to detect and eliminate the disease in its earliest and most effectively treated stages."
A first since January 2017
The JGH is introducing a new targeted therapy as part of the treatment strategy: brachytherapy. Since the implementation of a new research protocol which tests two new strategies in radiation therapy, a small group of patients has been able to avoid surgery as a form of treatment, because their tumour disappeared after radiation therapy and chemotherapy, according to Dr. Vuong in this video:
Media Relations: Emmanuelle Paciullo | firstname.lastname@example.org | 514 340-8222, ext. 4120 | Pager: 514-413-1289
CIUSSS West-Central Montreal: Serving a population of nearly 345,000 with more than 9,000 employees, including 900 doctors